The localization strategy of domestic pharmaceutical enterprises has been upgraded, and the transformation to innovation has become a trend

【Pharmaceutical Network Market Analysis】Recently, Carestream Health released two new intelligent imaging solutions, DRX-Rise mobile photography X-ray machine and Wave high-pressure syringe, for the first time in the Chinese market
.
The relevant person in charge said that this is a key step taken by Carestream Medical to the domestic market, and it is also an important decision
made by the company around the change of national policies and development direction.
Carestream Health is trying to broaden its product pipeline, and in the future, the company will continue to tailor products for all levels of the domestic market, and provide broader solutions, so as to achieve full coverage of high-end, high-end and low-end products in the Chinese market, so that innovation can benefit more people
.
Industry analysts believe that Carestream Healthcare's move is not only another innovation breakthrough, but also an accelerated upgrade of Carestream Healthcare's localization strategy, focusing on an exploration
of the domestic market at all levels.
Behind these results, Carestream Health's local strategy of rooting in China has gradually emerged
.
In fact, in recent years, with the introduction and landing of a series of policies to encourage the research and development of new drugs, the innovation vitality of China's biopharmaceutical industry has been continuously improved, and it is playing an increasingly important role
in the global pharmaceutical innovation map.
At the same time, the localization strategy of domestic pharmaceutical enterprises is also accelerating
.
It is understood that Haisco, established in 2000, has completed a strategic transformation
by reducing its product line.
Haisco, which participated in the first and second rounds of centralized procurement, quickly cut off its products in the face of the centralized procurement strategy, reducing the number of products from 30 to 6
.
Although this decision cost Haisco 60 million yuan, in the later rounds of collective procurement, all the remaining 6 products of Haisco won the bid
.
At present, Haisco invests more than 1 billion
yuan in R&D every year.
In addition, Hengrui has already transformed
from generic drugs to innovative drugs.
At present, nearly 100 projects are under research, the proportion of generic drugs is getting smaller and smaller, the proportion of innovative drugs is increasing, and the R&D pipeline is dominated
by innovative drugs.
Unlike Hengrui, Jimin Trust, which received a $500 million license-out cooperation, has formulated a strategy from Innovation 1.
0 to Innovation 3.
0, and is accumulating strength
by building a research platform and determining specific R&D pipelines.
In addition, it is worth mentioning that while Chinese innovative pharmaceutical enterprises are trying their best to display "Chinese intelligent medicine" through transformation and upgrading to innovation, multinational pharmaceutical companies are also actively integrating into the "localization trend"
.
For example, GE Healthcare, as the first global medical device innovation brand to enter the Chinese market after the reform and opening up, has taken Beijing as the forefront of the implementation of a comprehensive domestic strategy, and built a highly internationally competitive and stable supply chain
for the coordinated development of the Beijing-Tianjin-Hebei industry.
In addition, Pfizer has also been deeply cultivating the Chinese market, using scientific innovation to help 'Healthy China 2030', and contributing to the high-quality development of China's economy
.
" This year, we signed a localized production agreement with Huahai Pharmaceutical on nematevir tablets/ritonavir tablets, and promoted the localized production
of nematevir tablets/ritonavir tablets with practical actions.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.